General Information of Drug (ID: DMSYLIJ)

Drug Name
LARGAZOLE Drug Info
Synonyms LARGAZOLE; CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
24757913
CAS Number
CAS 1009815-87-5
TTD Drug ID
DMSYLIJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [2]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [2]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [2]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [2]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [2]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [2]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [2]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [2]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [2]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Cutaneous T-cell lymphoma 2B01 Approved [3]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [4]
Panobinostat DM58WKG Multiple myeloma 2A83 Approved [3]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [5]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [6]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [7]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [8]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [9]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 4 (HDAC4) TTTQGH8 HDAC4_HUMAN Inhibitor [1]

References

1 Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
2 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
3 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
7 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
8 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
9 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
10 2011 Pipeline of 4SC AG.